Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

Stopped early · Early Phase 1

Conditions studied: Metabolic Syndrome

In brief

The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance.

Key facts

Study ID
NCT00574834
Run by
University of Maryland, Baltimore
People needed
17
Starts
2007-03-01
Expected to finish
2014-08-01
Last updated by the study team
2019-09-12

Who can join

Age: 20 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.